



PTO/SB/08a (05-03)

Approved for use through 04/30/2003. OMB 0651-0031

U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449A/PTO

**INFORMATION DISCLOSURE
STATEMENT BY APPLICANT**

(use as many sheets as necessary)

Sheet 1 of 3

Complete if Known

Application Number	09/977,865
Filing Date	October 15, 2001
First Named Inventor	J. Kevin DONAHUE
Art Unit	1636
Examiner Name	K. Katcheves
Attorney Docket Number	001107.00449

U.S. PATENT DOCUMENTS

Examiner Initials *	Cite No. ¹	Document Number	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear
		Number - Kind Code ² (if known)			
K		2002/0094326 A1	07/18/2002	Donahue et al.	
		6,100,270	08/08/2000	Campbell	

FOREIGN PATENT DOCUMENTS

Examiner Initials *	Cite No. ¹	Foreign Patent Document	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear	T ⁶
		Country Code ³ - Number ⁴ - Kind Code ⁵ (if known)				
K		WO 96/16657	06/06/1996	Campbell		
		WO 99/19792	04/22/1999	Lawrence		
		WO 99/31982	07/01/1999	Stedman		

OTHER PRIOR ART -- NON PATENT LITERATURE DOCUMENTS

Examiner Initials *	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ²
K		Lamping, K. et al., "Agonist-specific impairment of coronary vascular function in genetically altered, hyperlipidemic mice," <i>Am. J. of Phys.</i> , (April 1999), pp. R1023-R1029, Vol. 276, no. 4	
		Kuwahara, A. et al., "5-HT activates nitric oxide-generating neurons to stimulate chloride secretion in guinea pig distal colon," <i>Am. J. Phys.</i> , (October 1998), pp. G829-G834, Vol. 275, no. 4	
		Frieden, M. et al., "Effect of 5-hydroxytryptamine on the membrane potential of endothelial and smooth muscle cells in the pig coronary artery," <i>British Journal of Pharmacology</i> , (1995), pp. 95- 100, Vol. 115, no. 1	
		Reiser, G., "Nitric oxide formation caused by calcium release from internal stores in neuronal cell line in enhanced by cyclic amp," <i>European Journal of Pharmacology Molecular Pharmacology Section</i> , (1992), pp. 89-93, Vol. 9, no. 1	
		Katz, S. et al., "Acute type 5 phosphodiesterase inhibition with sildenafil enhances flow-mediated vasodilation in patients with chronic heart failure," <i>Journal of the American College of Cardiology</i> , (September 2000), pp. 845-851, Vol. 36, No. 3	

Examiner Signature	<i>Konstantina Kottlun</i>	Date Considered	8/5/05
-----------------------	----------------------------	--------------------	--------

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. 1 Applicant's unique citation designation number (optional). 2 See Kinds Codes of USPTO Patent Documents at www.uspto.gov or MPEP 901.04. 3 Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). 4 For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. 5 Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. 6 Applicant is to place a check mark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 and select option 2.



PTO/SB/08a (05-03)

Approved for use through 04/30/2003. OMB 0651-0031

U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449A/PTO				Complete if Known	
				Application Number	09/977,865
INFORMATION DISCLOSURE STATEMENT BY APPLICANT (use as many sheets as necessary)				Filing Date	October 15, 2001
				First Named Inventor	J. Kevin DONAHUE
				Art Unit	1636
				Examiner Name	K. Katcheves
				Attorney Docket Number	001107.00449
Sheet	2	of	3		

U.S. PATENT DOCUMENTS					
Examiner Initials *	Cite No. ¹	Document Number	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear
		Number - Kind Code ² (if known)			

FOREIGN PATENT DOCUMENTS						
Examiner Initials *	Cite No. ¹	Foreign Patent Document	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear	T ⁶
		Country Code ³ - Number ⁴ - Kind Code ⁵ (if known)				

OTHER PRIOR ART -- NON PATENT LITERATURE DOCUMENTS			
Examiner Initials *	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ²
		Lai, N.C. et al., "Sodium nitroprusside facilitates intracoronary gene transfer in pigs," <i>Faseb Journal</i> , (March 2001), p. A100, Vol. 15, No. 4	
		Bilbao, R. et al., "A blood-tumor barrier limits gene transfer to the experimental liver cancer: The effect of vasoactive compounds," <i>Gene Therapy</i> , (November 2000), pp. 1824-1832, Vol. 7, no. 21	
		Corbin, J.D., et al., "Pharmacology of Phosphodiesterase-5 Inhibitors," <i>IJCP</i> , (July/August 2002), pp. 453-459, Vol. 56, No. 6	
		Eardly, I. et al., "Tadalafil (Cialis) for Men with Erectile Dysfunction," <i>IJCP</i> , (May 2002), pp. 300-304, Vol. 56, No. 4	
		Donahue, J.K. et al., "Ultrarapid, highly efficient viral gene transfer to the heart," <i>PNAS</i> , (April 1997), pp. 4664-4668, Vol. 94	

Examiner Signature	<i>K. Katcheves</i>	Date Considered	8/5/05
-----------------------	---------------------	--------------------	--------

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. 1 Applicant's unique citation designation number (optional). 2 See Kinds Codes of USPTO Patent Documents at www.uspto.gov or MPEP 901.04. 3 Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). 4 For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. 5 Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. 6 Applicant is to place a check mark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 and select option 2.



PTO/SB/08b(05-03)

Approved for use through 04/30/2003. OMB 0651-0031

U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number

Substitute for form 1449A/PTO		Complete if Known	
		Application Number	09/977,865
INFORMATION DISCLOSURE STATEMENT BY APPLICANT (use as many sheets as necessary)		Filing Date	October 15, 2001
		First Named Inventor	J. Kevin DONAHUE
		Group Art Unit	1636
		Examiner Name	K. Katcheves
		Attorney Docket Number	001107.00449
Sheet	3	of	3

OTHER PRIOR ART - NON PATENT LITERATURE DOCUMENTS			
Examiner Initials *	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ²
✓		Donahue, J.K. et al., "Acceleration of widespread adenoviral gene transfer to intact rabbit hearts by coronary perfusion with low calcium and serotonin," <i>Gene Therapy</i> , (1998), pp. 630-634, Vol. 5	
		Hetman, J.M. et al., "Cloning and characterization of PDE7B a cAMP-specific phosphodiesterase," <i>PNAS</i> , (January 2004), pp. 472-476, Vol. 97, No. 1	
		Nagata, K. et al., "Phosphodiesterase Inhibitor-mediated Potentiation of Adenovirus Delivery to Myocardium," <i>J. Mol. Cell Cardiol.</i> , (2001), pp. 575-580, Vol. 33	
		Sung, B. et al., "Structure of the catalytic domain of human phosphodiesterase 5 with bound drug molecules," <i>Nature</i> , (September 2003), pp. 98-102, Vol. 425	
		Lenhart, S.E. et al., "Preservation of myocardial function after adenoviral gene transfer in isolated myocardium," <i>Am. J. Physiol. Heart Circ. Physiol.</i> , (2000), pp. H986-H991, Vol. 278	
		Rotella, D., "Phosphodiesterase 5 Inhibitors: Current Status and Potential Applications," <i>Nature</i> , (September 2002), pp. 674-682, Vol. 1	
		Soderling, S.H. et al., "Cloning and characterization of a cAMP-specific cyclic nucleotide phosphodiesterase," <i>PNAS</i> , (July 1998), pp. 8991-8996, Vol. 95	
		Barr, E. et al., "Efficient catheter-mediated gene transfer into the heart using replication-defective adenovirus," <i>Gene Therapy</i> , (January 1994), pp. 51-8, Vol. 1, No. 1 (Abstract Only)	
		Ding, Z. et al., "A minimally invasive approach for efficient gene delivery to rodent hearts," <i>Gene Therapy</i> , (February 2004), pp. 260-265, Vol. 11, No. 3 (Abstract Only)	
		Inoue H. et al., "T-1032, a novel specific phosphodiesterase type 5 inhibitor, increases venous compliance in anesthetized rats," <i>Eur J. Pharmacol.</i> , (June 2001), pp. 109-114, Vol. 422, No. 1-3 (Abstract Only)	
✓		Takagi, M. et al., "Pharmacological profile of T-1032, a novel specific phosphodiesterase type 5 inhibitor, in isolated rat aorta and rabbit corpus cavernosum," <i>Eur J. Pharmacol.</i> , (January 2001), pp. 161-168, Vol. 411, No. 1-2 (Abstract Only)	

Examiner Signature	<i>Konstantina Katcheva</i>	Date Considered	8/5/05
--------------------	-----------------------------	-----------------	--------

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

1 Applicant's unique citation designation number (optional). 2 Applicant is to place a check mark here if English language Translation is attached. This collection of information is required by 37 CFR 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 120 minutes to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 and select option 2.